Notwithstanding positive clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant opposition from pharmacy benefit managers. The organizations are often building limitations to access, including high cost criteria and prior authorization that limit user availability.